A Field Trial of Oil Adjuvanten Trivalent Actinobacillus pleuropneumoniae Vaccine
The trivalent vaccine of A. pleuropneumoniae serotype 1, 2 and 5 (AP3V) was prepared in the oil-in-water type adjuvanten form. At an SPF farm, the vaccinated pigs were observed for their antibody response, finishing rate, and lung lesions at the time of slaughter and for injection scars. The CF tite...
Gespeichert in:
| Veröffentlicht in: | Journal of Veterinary Medical Science 1997, Vol.59(5), pp.421-423 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 423 |
|---|---|
| container_issue | 5 |
| container_start_page | 421 |
| container_title | Journal of Veterinary Medical Science |
| container_volume | 59 |
| creator | OISHI, Eiji KITAJIMA, Takashi NAKAMURA, Hisae MATSUDA, Chieko AMIMOTO, Katsuhiko YASUHARA, Hisao |
| description | The trivalent vaccine of A. pleuropneumoniae serotype 1, 2 and 5 (AP3V) was prepared in the oil-in-water type adjuvanten form. At an SPF farm, the vaccinated pigs were observed for their antibody response, finishing rate, and lung lesions at the time of slaughter and for injection scars. The CF titers against serotype 1, 2 and 5 started to rise after the second injection, showed the highest titer at 30 days after injection and then gradually decreased in vaccinated pigs. The finishing rate in the vaccinated group was 91.6% and that in the control group immunized with commercial vaccine was 60%. The lungs in the control pigs showed severe pneumonia with hyperemia, pleural adhesion and abscess. In contrast, vaccinated pigs showed slight pneumonia. Injection scars were not observed in vaccinated pigs 100 days after the second injection. In conclusion, the pigs immunized with AP3V were sufficiently protected against A. pleuropneumoniae infection and the trial proved to be satisfactory in the safety of the vaccine under field conditions. |
| doi_str_mv | 10.1292/jvms.59.421 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79085983</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79085983</sourcerecordid><originalsourceid>FETCH-LOGICAL-c629t-fa969813849a6a4c00c09f4d2e630cb901992b6f9a9fa4c15bf2536564d344133</originalsourceid><addsrcrecordid>eNqFkU1r3DAQhkVoSTcfp54LhkIvxVt923PLEpq0EAiFJFchy-NWRpa3kr3Qfx8vu-whl140oOfhhZmXkI-MrhkH_q3fDXmtYC05OyMrJmRVVlLAO7KiwHRZcUU_kIuce0o5kxrOyTkw4KKiK_JrU9x5DG3xlLwNxdgVjz4Um7afdzZOGPf_OxswTsXGTT6OjXU-hDkX24BzGrcR52GM3mLxYp3zEa_I-86GjNfHeUme774_3f4oHx7vf95uHkqnOUxlZ0FDzUQtwWorHaWOQidbjlpQ1wBlALzRHVjoFsxU03EltNKyFVIyIS7Jl0PuNo1_Z8yTGXx2GIKNOM7ZVEBrBfX_RQaKV5RXi_j5jdiPc4rLEmY5W60rocQ-7uvBcmnMOWFntskPNv0zjJp9H2bfh1Fglj4W-9Mxc24GbE_usYCF3xx4nyf7G0_cpsm7gKcsdXiWyBNyf2wyGMUrofCcZA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1468673533</pqid></control><display><type>article</type><title>A Field Trial of Oil Adjuvanten Trivalent Actinobacillus pleuropneumoniae Vaccine</title><source>MEDLINE</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>OISHI, Eiji ; KITAJIMA, Takashi ; NAKAMURA, Hisae ; MATSUDA, Chieko ; AMIMOTO, Katsuhiko ; YASUHARA, Hisao</creator><creatorcontrib>OISHI, Eiji ; KITAJIMA, Takashi ; NAKAMURA, Hisae ; MATSUDA, Chieko ; AMIMOTO, Katsuhiko ; YASUHARA, Hisao</creatorcontrib><description>The trivalent vaccine of A. pleuropneumoniae serotype 1, 2 and 5 (AP3V) was prepared in the oil-in-water type adjuvanten form. At an SPF farm, the vaccinated pigs were observed for their antibody response, finishing rate, and lung lesions at the time of slaughter and for injection scars. The CF titers against serotype 1, 2 and 5 started to rise after the second injection, showed the highest titer at 30 days after injection and then gradually decreased in vaccinated pigs. The finishing rate in the vaccinated group was 91.6% and that in the control group immunized with commercial vaccine was 60%. The lungs in the control pigs showed severe pneumonia with hyperemia, pleural adhesion and abscess. In contrast, vaccinated pigs showed slight pneumonia. Injection scars were not observed in vaccinated pigs 100 days after the second injection. In conclusion, the pigs immunized with AP3V were sufficiently protected against A. pleuropneumoniae infection and the trial proved to be satisfactory in the safety of the vaccine under field conditions.</description><identifier>ISSN: 0916-7250</identifier><identifier>EISSN: 1347-7439</identifier><identifier>DOI: 10.1292/jvms.59.421</identifier><identifier>PMID: 9192370</identifier><language>eng</language><publisher>Japan: JAPANESE SOCIETY OF VETERINARY SCIENCE</publisher><subject>Actinobacillus Infections - immunology ; Actinobacillus Infections - prevention & control ; Actinobacillus Infections - veterinary ; Actinobacillus pleuropneumoniae ; Adjuvants, Immunologic ; Animals ; Antibodies, Bacterial - blood ; Antibody Formation ; Bacterial Vaccines - adverse effects ; field trial ; Lung - microbiology ; Lung - pathology ; Oils ; Swine ; Swine Diseases ; vaccine ; Water</subject><ispartof>Journal of Veterinary Medical Science, 1997, Vol.59(5), pp.421-423</ispartof><rights>1997 by the Japanese Society of Veterinary Science</rights><rights>Copyright Japan Science and Technology Agency 1997</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c629t-fa969813849a6a4c00c09f4d2e630cb901992b6f9a9fa4c15bf2536564d344133</citedby><cites>FETCH-LOGICAL-c629t-fa969813849a6a4c00c09f4d2e630cb901992b6f9a9fa4c15bf2536564d344133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9192370$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OISHI, Eiji</creatorcontrib><creatorcontrib>KITAJIMA, Takashi</creatorcontrib><creatorcontrib>NAKAMURA, Hisae</creatorcontrib><creatorcontrib>MATSUDA, Chieko</creatorcontrib><creatorcontrib>AMIMOTO, Katsuhiko</creatorcontrib><creatorcontrib>YASUHARA, Hisao</creatorcontrib><title>A Field Trial of Oil Adjuvanten Trivalent Actinobacillus pleuropneumoniae Vaccine</title><title>Journal of Veterinary Medical Science</title><addtitle>J. Vet. Med. Sci.</addtitle><description>The trivalent vaccine of A. pleuropneumoniae serotype 1, 2 and 5 (AP3V) was prepared in the oil-in-water type adjuvanten form. At an SPF farm, the vaccinated pigs were observed for their antibody response, finishing rate, and lung lesions at the time of slaughter and for injection scars. The CF titers against serotype 1, 2 and 5 started to rise after the second injection, showed the highest titer at 30 days after injection and then gradually decreased in vaccinated pigs. The finishing rate in the vaccinated group was 91.6% and that in the control group immunized with commercial vaccine was 60%. The lungs in the control pigs showed severe pneumonia with hyperemia, pleural adhesion and abscess. In contrast, vaccinated pigs showed slight pneumonia. Injection scars were not observed in vaccinated pigs 100 days after the second injection. In conclusion, the pigs immunized with AP3V were sufficiently protected against A. pleuropneumoniae infection and the trial proved to be satisfactory in the safety of the vaccine under field conditions.</description><subject>Actinobacillus Infections - immunology</subject><subject>Actinobacillus Infections - prevention & control</subject><subject>Actinobacillus Infections - veterinary</subject><subject>Actinobacillus pleuropneumoniae</subject><subject>Adjuvants, Immunologic</subject><subject>Animals</subject><subject>Antibodies, Bacterial - blood</subject><subject>Antibody Formation</subject><subject>Bacterial Vaccines - adverse effects</subject><subject>field trial</subject><subject>Lung - microbiology</subject><subject>Lung - pathology</subject><subject>Oils</subject><subject>Swine</subject><subject>Swine Diseases</subject><subject>vaccine</subject><subject>Water</subject><issn>0916-7250</issn><issn>1347-7439</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1r3DAQhkVoSTcfp54LhkIvxVt923PLEpq0EAiFJFchy-NWRpa3kr3Qfx8vu-whl140oOfhhZmXkI-MrhkH_q3fDXmtYC05OyMrJmRVVlLAO7KiwHRZcUU_kIuce0o5kxrOyTkw4KKiK_JrU9x5DG3xlLwNxdgVjz4Um7afdzZOGPf_OxswTsXGTT6OjXU-hDkX24BzGrcR52GM3mLxYp3zEa_I-86GjNfHeUme774_3f4oHx7vf95uHkqnOUxlZ0FDzUQtwWorHaWOQidbjlpQ1wBlALzRHVjoFsxU03EltNKyFVIyIS7Jl0PuNo1_Z8yTGXx2GIKNOM7ZVEBrBfX_RQaKV5RXi_j5jdiPc4rLEmY5W60rocQ-7uvBcmnMOWFntskPNv0zjJp9H2bfh1Fglj4W-9Mxc24GbE_usYCF3xx4nyf7G0_cpsm7gKcsdXiWyBNyf2wyGMUrofCcZA</recordid><startdate>19970501</startdate><enddate>19970501</enddate><creator>OISHI, Eiji</creator><creator>KITAJIMA, Takashi</creator><creator>NAKAMURA, Hisae</creator><creator>MATSUDA, Chieko</creator><creator>AMIMOTO, Katsuhiko</creator><creator>YASUHARA, Hisao</creator><general>JAPANESE SOCIETY OF VETERINARY SCIENCE</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QR</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7QL</scope><scope>C1K</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>19970501</creationdate><title>A Field Trial of Oil Adjuvanten Trivalent Actinobacillus pleuropneumoniae Vaccine</title><author>OISHI, Eiji ; KITAJIMA, Takashi ; NAKAMURA, Hisae ; MATSUDA, Chieko ; AMIMOTO, Katsuhiko ; YASUHARA, Hisao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c629t-fa969813849a6a4c00c09f4d2e630cb901992b6f9a9fa4c15bf2536564d344133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Actinobacillus Infections - immunology</topic><topic>Actinobacillus Infections - prevention & control</topic><topic>Actinobacillus Infections - veterinary</topic><topic>Actinobacillus pleuropneumoniae</topic><topic>Adjuvants, Immunologic</topic><topic>Animals</topic><topic>Antibodies, Bacterial - blood</topic><topic>Antibody Formation</topic><topic>Bacterial Vaccines - adverse effects</topic><topic>field trial</topic><topic>Lung - microbiology</topic><topic>Lung - pathology</topic><topic>Oils</topic><topic>Swine</topic><topic>Swine Diseases</topic><topic>vaccine</topic><topic>Water</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OISHI, Eiji</creatorcontrib><creatorcontrib>KITAJIMA, Takashi</creatorcontrib><creatorcontrib>NAKAMURA, Hisae</creatorcontrib><creatorcontrib>MATSUDA, Chieko</creatorcontrib><creatorcontrib>AMIMOTO, Katsuhiko</creatorcontrib><creatorcontrib>YASUHARA, Hisao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Chemoreception Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Veterinary Medical Science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OISHI, Eiji</au><au>KITAJIMA, Takashi</au><au>NAKAMURA, Hisae</au><au>MATSUDA, Chieko</au><au>AMIMOTO, Katsuhiko</au><au>YASUHARA, Hisao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Field Trial of Oil Adjuvanten Trivalent Actinobacillus pleuropneumoniae Vaccine</atitle><jtitle>Journal of Veterinary Medical Science</jtitle><addtitle>J. Vet. Med. Sci.</addtitle><date>1997-05-01</date><risdate>1997</risdate><volume>59</volume><issue>5</issue><spage>421</spage><epage>423</epage><pages>421-423</pages><issn>0916-7250</issn><eissn>1347-7439</eissn><abstract>The trivalent vaccine of A. pleuropneumoniae serotype 1, 2 and 5 (AP3V) was prepared in the oil-in-water type adjuvanten form. At an SPF farm, the vaccinated pigs were observed for their antibody response, finishing rate, and lung lesions at the time of slaughter and for injection scars. The CF titers against serotype 1, 2 and 5 started to rise after the second injection, showed the highest titer at 30 days after injection and then gradually decreased in vaccinated pigs. The finishing rate in the vaccinated group was 91.6% and that in the control group immunized with commercial vaccine was 60%. The lungs in the control pigs showed severe pneumonia with hyperemia, pleural adhesion and abscess. In contrast, vaccinated pigs showed slight pneumonia. Injection scars were not observed in vaccinated pigs 100 days after the second injection. In conclusion, the pigs immunized with AP3V were sufficiently protected against A. pleuropneumoniae infection and the trial proved to be satisfactory in the safety of the vaccine under field conditions.</abstract><cop>Japan</cop><pub>JAPANESE SOCIETY OF VETERINARY SCIENCE</pub><pmid>9192370</pmid><doi>10.1292/jvms.59.421</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0916-7250 |
| ispartof | Journal of Veterinary Medical Science, 1997, Vol.59(5), pp.421-423 |
| issn | 0916-7250 1347-7439 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79085983 |
| source | MEDLINE; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Actinobacillus Infections - immunology Actinobacillus Infections - prevention & control Actinobacillus Infections - veterinary Actinobacillus pleuropneumoniae Adjuvants, Immunologic Animals Antibodies, Bacterial - blood Antibody Formation Bacterial Vaccines - adverse effects field trial Lung - microbiology Lung - pathology Oils Swine Swine Diseases vaccine Water |
| title | A Field Trial of Oil Adjuvanten Trivalent Actinobacillus pleuropneumoniae Vaccine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T15%3A38%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Field%20Trial%20of%20Oil%20Adjuvanten%20Trivalent%20Actinobacillus%20pleuropneumoniae%20Vaccine&rft.jtitle=Journal%20of%20Veterinary%20Medical%20Science&rft.au=OISHI,%20Eiji&rft.date=1997-05-01&rft.volume=59&rft.issue=5&rft.spage=421&rft.epage=423&rft.pages=421-423&rft.issn=0916-7250&rft.eissn=1347-7439&rft_id=info:doi/10.1292/jvms.59.421&rft_dat=%3Cproquest_cross%3E79085983%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1468673533&rft_id=info:pmid/9192370&rfr_iscdi=true |